51���� will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN.

51���� will be in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

51���� will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN.

51���� will attend The 2025 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.

51���� will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.

51���� is sponsoring and will attend Alport Connect 2025 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.

51���� will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.

51���� will attend the the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

51���� will attend the 7th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.

51���� will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

51���� will also take the opportunity to host an executive roundtable at on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.

51���� will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
51���� will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.